Second-quarter earnings season is just around the corner and it's probably not going to turn any heads. Here's a preview of what to expect More
-
Sponsored By:
-
Sponsored By:
-
Sponsored By:
MJN
Recent Articles
What To Make Of Tuesday’s Surprising Market Move
Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here's our new research on 50 stocks in Portfolio Grader More
Avoid the Mistake That Investors Are Making Right Now
Wall Street finished up on a high note Monday, including a record for the S&P 500, led by tech stocks. Here is the list of our updated buys, sells, and holds. More
Blue Chips Making Waves and Changing Ratings
With the runup in the markets over the past week a lot has changed in the valuations of companies. Take a look at our latest listing to find out where we stand More
Zoetis: The Biggest IPO Since Facebook
Pfizer's animal health division, Zoetis, could raise more than $2 billion, making it the largest IPO since Facebook. Here's a look at the Zoetis deal, as well as three others on tap for this week. More
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome. More
Mead Johnson: A Formula for Success
The maker of infant formula and pediatric products is a perpetual winner, with strong growth in foreign markets as well. More
